Location Austin, Texas, United States Regions Southern US Gender Male Also Known As Dr. Steven Idell
LinkedIn View on LinkedIn
Steven Idell, M.D., Ph.D. is the Founder and Chief Scientific Officer at Lung Therapeutics, Inc. Steven is a clinical investigator who has been continuously funded over the past 25 years by the National Institutes of Health for his work in the areas of acute lung injury and pleural diseases.
Steven is a board-certified internist and
pulmonologist who has also directed the Intensive Care Units at Temple University Hospital in Philadelphia and at The University of Texas Health Science Center at Tyler, Texas.
Steven is now Vice President for Research, a Professor of Medicine and Temple Chair of Pulmonary Fibrosis at UTHSCT and Director of an NIH-sponsored Program Project Grant to study the role of the fibrinolytic system in the pathogenesis of lung and pleural disease. Work from that project led to the development of scuPA as a treatment for pleural loculation and of a peptide-based approach to treat acute lung injury and pulmonary fibrosis.
Steven also continues to manage patients in the UTHSCT Pulmonary Clinic. Steven has successfully obtained over $17 million in grant support from agencies including the NIH, The American Heart Association, The American Lung Association and various foundations. Steven is the Director of the Texas Lung Injury Institute of UTHCT and has raised nearly $1 million of philanthropic support for lung injury research to develop novel experimental therapeutics from the community, grateful patients and various foundations in East Texas and has received commitment from the NIH RAID and SMARTT programs to perform IND-enabling studies with his lead therapeutic, LTI-01.
In addition to his role as CSO, Steven also serves as Chair of the Scientific Advisory Board and a Member of the Board of Directors.
Steven received his M.D. from Temple University School of Medicine in Philadelphia in 1977, followed by a Ph.D. in Physiology in 1987 from the same institution. Steven specialized in research into thrombosis, the process by which blood clots, as well as clot destruction and how these processes relate to the pathogenesis of lung injury and repair.
